To observe the clinical efficacy of trimetazidine combined with metoprolol in the treatment of senile coronary heart disease (CHD) combined with heart failure (CHF).

A total of 110 elderly patients with CHD combined with CHF admitted to Xinzheng People’s Hospital from May 2017 to May 2018 were randomly divided into control group and observation group, 55 patients in each group. Patients in group A received trimetazidine on the basis of routine treatment, and patients in group B received metoprolol on the basis of treatment in group A. The levels of inflammatory factors such as LVEF, LVEDD, LVESD and the inflammatory factors such as IL-6, TNF-α were compared before and after treatment in the two groups.

The total effective rate of the observation group (98.11%) was higher than that of the control group (81.82%), and the difference was statistically significant (P<0.05). The level of LVEF after treatment in the observation group was higher than that in the control group, and the levels of LVEDD and LVESD in the observation group were lower than those in the control group (P<0.05). The levels of IL-6 and TNF-a after treatment in the observation group were lower than those in the control group (P<0.05).

Trimetazidine combined with metoprolol in the treatment of elderly CHD with CHF has a good clinical effect, can effectively improve the cardiac function of patients, and can inhibit inflammation. It has clinical popularization value.